Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioDiab
- Development stage
- Unknown
- Lead developer
- Takgene
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BioDiab is an orally administered probiotic supplement developed by Takgene (Takgene Pharma) and marketed by its subsidiary Novagen Pharmed. It is formulated as a capsule containing a blend of six probiotic strains: Bacillus coagulans, Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis, Lactobacillus casei, Bifidobacterium longum, and Bifidobacterium bifidum. BioDiab is designed to assist in the management of type 2 diabetes mellitus and prediabetes by regulating metabolic activities and improving glycemic control. The probiotic strains in BioDiab work by modulating the gut microbiota, reducing insulin resistance, improving HbA1c and fasting insulin levels, and decreasing oxidative stress and systemic inflammation. Downstream mechanisms include the production of short-chain fatty acids (such as butyrate) and bile salt hydrolase (BSH) enzymes, which subsequently activate farnesoid X receptors (FXR) and stimulate the secretion of glucagon-like peptides (GLP-1 and GLP-2) to enhance insulin synthesis and secretion.
- Brand names
- BioDiab
- Other names
- Bio DiabBiodiabTakgene Pharma Bio DiabTakgene Pharma BioDiab
Beyond the preview
Go deeper on BioDiab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioDiab.